How ApoE4 May Increase Alzheimer’s Risk
Posted by SR in News, tags: alzheimer's, mechanismApoE interacts with members of the LDL receptor family and one of the receptors for ApoE, Apoer2, also acts as a signalling receptor for reelin, a protein that is important in the developing brain but also enhances NMDA receptor activity and increases long-term potentiation (LTP) in the adult brain. ApoE4 was found to reduce surface expression of NMDA and AMPA receptors as well as Apoer2 receptors, thereby impairing glutamatergic neurotransmission. β-Amyloid peptide, a hallmark of Alzheimer’s disease, suppresses LTP and the ability of reelin to counter the effects of β-amyloid peptide was almost completely abolished in mice expressing human ApoE4. The team are now trying to understand whether it is possible to build on their findings to develop new treatments for Alzheimer’s disease.
The study is published in the Proceedings of the National Academy of Sciences.
Related posts:
- GPCR Target for Alzheimer’s Disease Available treatments for Alzheimer’s disease offer relatively small symptomatic benefits and more effective treatments are much needed. β-Amyloid has been...
- Nicotinic α-7 Receptors in Alzheimer’s Disease – On or Off? A number of groups are developing nicotinic α-7 receptor agonists or partial agonists for the treatment of Alzheimer’s disease. It...
- Paradoxical Results for Alzheimer’s Drug Although not without opponents – and still unproven – the theory that reducing levels of β-amyloid peptides will lessen neuronal...
- Prion Protein linked to Alzheimer’s Disease Mis-folded prion proteins have been linked to a number of neurological diseases including scrapie in sheep, bovine spongiform encephalopathy (BSE,...
- Hayfever Drug Shows Promise for Treatment of Alzheimer’s Disease A study published in the July 18th issue of The Lancet shows that a drug once used in Russia to...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Thursday, June 17th, 2010 at 10:25 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

















Entries (RSS)